Long-acting β2-agonists in asthma: Safety concerns

CMAJ. Canadian Medical Association Journal

Volumn 173, Issue 9, 2005, Pages 1030-1031

  Wooltorton, Eric ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; OXEZE; PLACEBO; SALMETEROL; SALMETEROL XINAFOATE; BETA 2 ADRENERGIC RECEPTOR; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; SALBUTAMOL;

ASTHMA; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG FATALITY; DRUG SAFETY; HUMAN; SHORT SURVEY; ARTICLE; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SAFETY;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ASTHMA; ETHANOLAMINES; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ADRENERGIC, BETA-2; RISK FACTORS; SAFETY;

EID: 27544470323     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.051224     Document Type: Short Survey

References (4)

1. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-7.
2. Wooltorton E. Salmeterol (Serevent) asthma trial halted early. CMAJ 2003;168(8):738.
3. Becker A, Lemière C, Bérubé D, Boulet LP, Ducharme FM, FitzGerald M, et al. Summary of recommendations from the Canadian Asthma Consensus Guidelines, 2003, and Canadian Pediatric Asthma Consensus Guidelines, 2003 (updated to December 2004). CMAJ 2005:173(6 Suppl):S1-56.
4. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003;124:70-4.